Notably, high levels of LBH were significantly associated with reduced overall and/or relapse-free patient survival in colon-rectal cancer (Fig. 3B.i–iii; Fig. S2A.i–ii), stomach cancer (Fig. S2A.iii–iv), pancreatic cancer (Fig. 3B.v–vi; Fig. S2.v), esophageal cancer (Fig. 3B.vii–viii; Fig. S2A.vi–vii), bladder cancer (Fig. 3B.ix–x), testicular cancer (Fig. 3B.xi), head and neck cancer (Fig. 3B.xii), sarcoma (Fig. S2A.viii), glioblastoma (Fig. S2A.ix–x), and Diffuse Large B-cell lymphoma (Fig. S2A.xi–xii), suggestive of an oncogenic role. The gene discussed is LBH; the disease is urinary bladder cancer.